[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphedema-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphedema-breast-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,73,101,127,164,186,222],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100467433","lympha-procedure-for-the-prevention-of-lymphedema-after-axillary-lymphadenectomy-100467433",false,"NCT05366699","LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy","A Randomized Clinical Trial of the LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy","Inclusion Criteria:\n\n* Ages 18 to 75 years (inclusive)\n* Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy\n* Free of distant metastasis in preoperative screening\n* Histology results of axillary lymph nodes could be either Negative or Positive\n* Patients who undergo preoperative chemotherapy can be included\n* Willingness and ability to provide written informed consent\n* Willingness and ability to comply with all study procedures\n\nExclusion Criteria:\n\n* Primary lymphedema of the affected upper limb\n* Secondary lymphedema of the affected limb prior to the lymphadenectomy\n* Radiotherapy at the axilla before the study \u002F surgery\n* Allergic reaction to porcine collagen or ICG\n* Receiving radiation therapy to the involved nodal basin in a period less than 4 weeks after the surgery\n* Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening\n* Other medical condition that could lead to limb edema, such as (but not limited to primary lymphedema or acute venous thrombosis\n* Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion)\n* Either of the following, at the time of baseline evaluation: ipsilateral:contralateral limb volume ratio\\>1.1 or R0 bioimpedance ratio \\> 1.106 when the nondominant limb is at risk, and 1.134 when the dominant limb is at risk.\n* Life expectancy \\\u003C 2 years for any reason\n* Pregnancy or nursing\n* Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening\n* Severe psychiatric disease\n* Significant or chronic renal insufficiency (defined as serum creatinine \\> 2.5 mg\u002FdL or an estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin at screening) or requires dialytic support\n* Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels \\> 3 × upper limit of the normal range (ULN) and\u002For bilirubin level \\> 2 × ULN at screening\n* Absolute neutrophil count \\\u003C 1500 mm3 at screening\n* Hemoglobin concentration \\\u003C 9 g\u002FdL at screening\n* Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study","FEMALE","18 Years","75 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema.\n\nAdditionally, to determine if this procedure improves objective outcomes of lymphedema and patient quality of life",[27,28],"Lymphedema, Breast Cancer","Lymphedema","RECRUITING","2026-06-18",{"date":32,"type":33},"2026-06-23","ACTUAL",{"date":35,"type":33},"2021-09-10",{"date":37,"type":21},"2030-06-01",{"name":39,"class":40},"Stanford University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100507691","the-lymph-trial---microsurgical-versus-conservative-treatment-of-chronic-breast-cancer-associated-lymphedema-100507691","NCT05890677","The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema","The LYMPH Trial - Comparing Microsurgical With Conservative Treatment of Chronic Breast Cancer Associated Lymphedema: Study Protocol of a Pragmatic Randomized International Multicentre Superiority Trial","LYMPH","Inclusion Criteria:\n\n* Written informed consent.\n* Patients ≥ 18 years of age.\n* Former diagnosis of breast cancer.\n* Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL.\n* Minimum of 3 months Conservative Complex Physical Decongestion Therapy.\n* Ability to complete the QoL questionnaires.\n* Willingness to undergo surgery.\n\nExclusion Criteria:\n\n* No indication for lymphatic surgery according to clinical judgment of the treating surgeon (individual reasons will be specifically documented).\n* Primary congenital Lymphedema or non-BCRL.\n* Previous surgical BCRL treatment on the side intended for intervention.","ALL",{"count":52,"type":21},280,[24],"The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)",[27],[57,58,59,60,61,62],"lymphatic surgery","breast cancer related lymphedema","sentinel lymph node biopsy","axillary lymph node dissection","manual lymphatic drainage","conservative complex physical decongestion therapy","2026-06-03",{"date":65,"type":33},"2026-06-04",{"date":67,"type":33},"2023-07-14",{"date":69,"type":21},"2036-06",{"name":71,"class":40},"University Hospital, Basel, Switzerland",36,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":18,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100612753","phase-4-gentle-touch-for-post-mastectomy-lymphedema-100612753","NCT07257679","Gentle Touch for Post-Mastectomy Lymphedema","The Effects of 'Gentle Touch' in the Management of Lymphedema in Women Treated for Breast Cancer: A Preliminary Single-blind, Parallel-group Randomized Controlled Trial.","GT-BCRL","Inclusion Criteria:\n\n* Gender: Women.\n* Age: Between 30 and 75 years old\n* Surgical History: Women who have undergone surgery for breast cancer (BC). This includes being subjected to one of the following interventions: Axillary dissection with removal of all 3 lymph node levels; Axillary dissection with removal of only one lymph node level; Removal of the sentinel lymph node only.\n* Clinical Lymphedema: Clinically evaluated lymphedema symptoms, defined as a circumference difference of greater than 20mm between the two arms\n\nExclusion Criteria:\n\n* Concurrent Diseases: Concomitant diseases that may interfere with the study.","30 Years",{"count":72,"type":21},[84],"PHASE4","This is a single-blind, parallel-group Randomized Controlled Trial (RCT) comparing the efficacy of a specialized manual technique, Gentle Touch (GT), versus a control intervention, both added to the usual rehabilitative care. The study investigates 36 women aged 30 to 75 with Breast Cancer-Related Lymphedema (BCRL). The primary objective is to evaluate the reduction of lymphedema volume in the upper limb. Secondary objectives include assessing the improvement in patients' quality of life and the potential reduction in care burden and costs. The treatment protocol involves 10 bi-weekly sessions over 5 weeks.",[27],[28,88,89,90],"Breast Cancer","DLM","Gentle touch","2025-11-27",{"date":93,"type":33},"2025-12-02",{"date":95,"type":33},"2025-11-01",{"date":97,"type":21},"2027-11-01",{"name":99,"class":40},"I.R.C.C.S. Fondazione Santa Lucia",2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100609646","complete-decongestive-therapy-versus-non-pneumatic-compression-therapy-in-post-mastectomy-lymphedema-100609646","NCT07217288","Complete Decongestive Therapy Versus Non-pneumatic Compression Therapy in Post Mastectomy Lymphedema","Effectiveness of Complete Decongestive-versus Non-pneumattic- Compression Therapy in Patients With Post-mastectomy Lymphedema","CDT","Inclusion Criteria:\n\n* Females with age between 30 to 60 years. (Monticciolo et al., 2021)\n* Females with unilateral mastectomy post three months of surgery. (Shen et al., 2023) 21\n* A volume difference to the circumferential measurements between the affected and unaffected upper extremities of more volume difference\\>10%.\n* Completed chemotherapy and\u002For radiation therapy. (Borman, Yaman, Yasrebi, İnanlı, \\& Dönmez, 2022)\n\nExclusion Criteria:\n\n* Systemic disorders that might contraindicate the use of sequential compression therapy i.e. chronic kidney disease with renal failure, Congestive heart failure, neurological disorders, respiratory disorders.\n* Presence of active cellulitis, open and partially healed wounds.\n* Patients with lipedema\n* Active or recurrent cancer (defined as \\\u003C 3 months since completion of cancer therapy)\n* An acute infection within the previous 4 weeks\n* Active venous thromboembolic edema\n* Pregnant women and women who are planning or nursing at study entry.\n* Patients who had participated in any clinical trial of an investigational substance or device during the previous 30 days\n* Potential patients with a cognitive or physical impairment that would interfere with appropriate use of the device. (Rockson, Whitworth, et al., 2022)","60 Years",{"count":111,"type":21},52,[24],"The aim of the study is to compare the effectiveness of Complete Decongestive Therapy and Non-Pneumatic Compression Therapy, both combined with routine physical therapy, in reducing pain and edema volume, improving range of motion, respiratory function, inflammatory markers, and overall quality of life in patients with post-mastectomy lymphedema.",[27,115,116],"Mastectomy Related Lymphedema","Post Mastectomy Lymphedema","NOT_YET_RECRUITING","2025-10-14",{"date":120,"type":33},"2025-10-15",{"date":122,"type":21},"2025-10-26",{"date":124,"type":21},"2027-04-30",{"name":126,"class":40},"Lahore University of Biological and Applied Sciences",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":146,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100606060","effectiveness-of-a-therapeutic-exercise-program-with-specific-upper-limb-exercises-to-reduce-lymphedema-and-neuropathy-in-breast-cancer-patients-a-pre-post-study-lynma-100606060","NCT07170631","Effectiveness of a Therapeutic Exercise Program With Specific Upper Limb Exercises to Reduce Lymphedema and Neuropathy in Breast Cancer Patients: A Pre-post Study (LYNMA)","Effectiveness of a General Therapeutic Exercise Program Including Specific Upper Limb Exercises to Reduce Lymphedema and Peripheral Neuropathy Secondary to Oncological Treatment in Patients With Breast Cancer: A Pre-post Intervention Study (LYNMA)","LYNMA","Inclusion Criteria:\n\n* Patients receiving treatment for breast carcinoma.reatments include surgical procedures (breast-conserving surgery or mastectomy), axillary lymph node dissection, sentinel lymph node biopsy, radiotherapy, chemotherapy, and hormone therapy.\n* Participants must provide authorization from their primary care physician and\u002For oncologist to perform therapeutic exercise.\n* Diagnosis of lymphedema associated with stage I or II breast cancer (Stage 1 or mild: circumference difference less than 4 cm \\[volume difference 10-25%\\] compared to the healthy arm; Stage 2 or moderate: circumference difference between 4 and 6 cm \\[volume difference 25-50%\\] compared to the healthy arm).\n* A score of 4 or higher on the DN4 questionnaire (neuropathic pain)\n\nExclusion Criteria:\n\n* Lack of medical authorization.\n* Pre-existing cardiac pathology prior to cancer diagnosis.\n* Exacerbation of comorbidities.\n* Travel time exceeding 45 minutes to the location where the therapeutic exercise program is conducted.","35 Years","70 Years",{"count":138,"type":21},30,[24],"This study aims to evaluate the effectiveness of a therapeutic exercise program designed specifically for women with breast cancer. The program includes general exercises along with specific movements for the upper limb to help reduce common side effects of cancer treatment such as lymphedema (swelling of the arm) and neuropathy (nerve pain or numbness). Participants will undergo the exercise program and be assessed before and after to determine improvements in their symptoms and overall quality of life. The goal is to provide evidence that targeted physical therapy can improve recovery and well-being in breast cancer survivors.",[142,143,27,144,145],"Lymphedema Arm","Lymphedema Due to Radiation","Peripheral Neuropathy Due to Chemotherapy","Peripheral Neuropathy in Breast Cancer Patient",[147,148,28,149,150,151,152,153,154],"Therapeutic exercise","Breast cancer","Peripheral neuropathy","Upper limb exercises","Oncology physiotherapy","Neural mobilization","Neurodynamic techniques","Peripheral nerve ultrasound","2025-09-12",{"date":157,"type":33},"2025-09-18",{"date":159,"type":21},"2026-01",{"date":161,"type":21},"2026-10",{"name":163,"class":40},"Universitat Internacional de Catalunya",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":41},"100485435","lymphovenous-anastomosis-to-prevent-breast-cancer-related-lymphedema-100485435","NCT05601037","LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema","Lymfo-Veneuse Anastomosen Ter Preventie Van Lymphoedeem","LVARCT","Inclusion Criteria:\n\n* lymph node + breast cancer requiring dissection\n\nExclusion Criteria:\n\n* previous lymphedema\n* BMI \\>35","99 Years",{"count":20,"type":21},[24],"Lymphedema is defined as a chronic condition, caused by lymphostasis. A major part in the Western world consists of iatrogenic lymphedema caused by surgery to the lymph nodes of the axilla or groin. Prophylactic lymphovenous anastomosis (LVA) could be beneficial in the prevention of lymphedema of the extremities.",[27],"2024-11-06",{"date":179,"type":33},"2024-11-08",{"date":181,"type":33},"2021-06-30",{"date":183,"type":21},"2026-12-27",{"name":185,"class":40},"University Hospital, Ghent",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":204,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":41},"100557041","the-robot-lva-study-robot-assisted-microsurgical-lymphaticovenous-anastomosis-in-breast-cancer-related-lymphedema-100557041","NCT06532955","The Robot-LVA Study: Robot-assisted Microsurgical Lymphaticovenous Anastomosis in Breast Cancer-related Lymphedema","Pilot Study on Robotic Assisted Microsurgical Lymphatico-venular Anastomosis","Inclusion Criteria:\n\n* Female gender;\n* Treated for primary early stage breast cancer;\n* Early stage lymphedema of the arm (stage 1 or 2 on ISL classification);\n* ELV \\> 10%;\n* Suffering from unilateral disease.\n\nExclusion Criteria:\n\n* Male gender;\n* Stage 3 lymphedema of the arm;\n* Receiving current breast cancer treatment;\n* Distant breast cancer metastases;\n* Current substance abuse;\n* History of marcaine or indocyanine green allergy;\n* Non-viable lymphatic system as determined by near infrared imaging;\n* Previous LVA (\\\u003C10 years) in the arm with lymphedema.",{"count":194,"type":21},60,[24],"This study assesses the performance of robot-assisted microsurgery. Lymphaticovenous anastomosis (LVA) is the most difficult procedure in microsurgery at this moment. The LVA technique is applied to treat for example breast cancer-related lymphedema (BCRL). Therefore, this LVA procedure is compared using a manual expert and the same expert applying robot-assisted LVA.",[28,142,198,199,200,201,202,27,203],"Lymphedema of Upper Arm","Lymphedema of Upper Limb","Lymphedema; Surgical","Lymphedema, Secondary","Lymphedema of Limb","Lymphedema, Non-Filarial",[205,206,207,208,209,210,211,212],"Robot-assisted microsurgery","Microsurgery","Robot","Robotic-assisted","Robot-assisted","Lymphaticovenous anastomosis","Lymphatico-venular anastomosis","LVA","2024-07-30",{"date":215,"type":33},"2024-08-01",{"date":217,"type":33},"2017-06-01",{"date":219,"type":21},"2026-01-01",{"name":221,"class":40},"Maastricht University Medical Center",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":41},"100430737","a-non-randomized-open-label-study-to-evaluate-the-safety-and-effectiveness-of-the-dayspring-technology-for-patients-with-breast-cancer-related-lymphedema-bcrl-after-lymphatic-surgery-100430737","NCT04888975","A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery","TIGRIS","Inclusion Criteria:\n\n* Males and females ≥ 18 years of age\n* Willing to sign the informed consent and deemed capable of following the study protocol\n* Subjects must have a diagnosis of upper extremity edema and have or will undergo lymphatic surgery with Dr. Nguyen\n* Subjects must have a difference in volume greater than 3% between the limbs.\n\nExclusion Criteria:\n\n* Individuals with a history or presence of a systemic disorder or condition that could place the patient at increased risk from sequential compression therapy\n* Inability or unwillingness to participate in all aspects of study protocol and\u002For inability to provide informed consent\n* Patients with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.)\n* Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial evaluation from the completion of chemotherapy, radiation therapy or primary surgery for the treatment of cancer\n* Patients must not have any diagnosed cognitive or physical impairment that would interfere with use of the device\n* Diagnosis of lipedema\n* Diagnosis of acute infection. The source of the infection must be treated for 2 weeks prior to admittance into the study\n* Diagnosis of acute thrombophlebitis (in last 2 months)\n* Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months\n* Diagnosis of pulmonary edema\n* Diagnosis of congestive heart failure (uncontrolled)\n* Diagnosis of chronic kidney disease\n* Diagnosis of epilepsy\n* Patients with poorly controlled asthma\n* Women who are pregnant, planning a pregnancy or nursing at study entry\n* Participation in any clinical trial of an investigational substance or device during the past 30 days\n* Bilateral limb edema",{"count":230,"type":21},20,[24],"To evaluate the Dayspring Active Wearable Compression Technology in enhancing lymph movement and its safety and effectiveness after lymphatic surgery",[28,27,142],"2021-05-18",{"date":236,"type":33},"2021-05-20",{"date":238,"type":21},"2021-06-01",{"date":240,"type":21},"2021-12-31",{"name":242,"class":243},"Koya Medical, Inc.","INDUSTRY"]